PLX Relative Valuation
PLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PLX is overvalued; if below, it's undervalued.
Historical Valuation
Protalix Biotherapeutics Inc (PLX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 4.45. The fair price of Protalix Biotherapeutics Inc (PLX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.75
Fair
10.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Protalix Biotherapeutics Inc. (PLX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -1.13, Undervalued between -1.13 and -0.41, Fairly Valued between 1.01 and -0.41, Overvalued between 1.01 and 1.72, and Strongly Overvalued above 1.72. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
10.88
EV/EBIT
Protalix Biotherapeutics Inc. (PLX) has a current EV/EBIT of 10.88. The 5-year average EV/EBIT is 4.28. The thresholds are as follows: Strongly Undervalued below -20.73, Undervalued between -20.73 and -8.22, Fairly Valued between 16.79 and -8.22, Overvalued between 16.79 and 29.29, and Strongly Overvalued above 29.29. The current Forward EV/EBIT of 10.88 falls within the Historic Trend Line -Fairly Valued range.
1.84
PS
Protalix Biotherapeutics Inc. (PLX) has a current PS of 1.84. The 5-year average PS is 1.96. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and 0.83, Fairly Valued between 3.08 and 0.83, Overvalued between 3.08 and 4.21, and Strongly Overvalued above 4.21. The current Forward PS of 1.84 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Protalix Biotherapeutics Inc. (PLX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.34. The thresholds are as follows: Strongly Undervalued below -1.22, Undervalued between -1.22 and -0.44, Fairly Valued between 1.12 and -0.44, Overvalued between 1.12 and 1.90, and Strongly Overvalued above 1.90. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Protalix Biotherapeutics Inc. (PLX) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.11. The thresholds are as follows: Strongly Undervalued below -3.85, Undervalued between -3.85 and -1.37, Fairly Valued between 3.59 and -1.37, Overvalued between 3.59 and 6.07, and Strongly Overvalued above 6.07. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Protalix Biotherapeutics Inc (PLX) has a current Price-to-Book (P/B) ratio of 2.61. Compared to its 3-year average P/B ratio of 14.07 , the current P/B ratio is approximately -81.44% higher. Relative to its 5-year average P/B ratio of 19.98, the current P/B ratio is about -86.93% higher. Protalix Biotherapeutics Inc (PLX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.87% , the current FCF yield is about -100.00% lower.
2.66
P/B
Median3y
14.07
Median5y
19.98
-8.45
FCF Yield
Median3y
-6.50
Median5y
-14.87
Competitors Valuation Multiple
The average P/S ratio for PLX's competitors is 0.00, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -0.60%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PLX decreased by 6.91% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 21.03 to 25.34.
The secondary factor is the Revenue Growth, contributed -0.60%to the performance.
Overall, the performance of PLX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Protalix Biotherapeutics Inc (PLX) currently overvalued or undervalued?
What is Protalix Biotherapeutics Inc (PLX) fair value?
How does PLX's valuation metrics compare to the industry average?
What is the current P/B ratio for Protalix Biotherapeutics Inc (PLX) as of Dec 05 2025?
What is the current FCF Yield for Protalix Biotherapeutics Inc (PLX) as of Dec 05 2025?
What is the current Forward P/E ratio for Protalix Biotherapeutics Inc (PLX) as of Dec 05 2025?